FAQ for Human APIs, Cortico-Steroids and Hormonal APIs.

Buyers can discuss APIs such as Amlodipine Besylate, Apixaban, Artemether, Artesunate, Ethambutol HCl, Esomeprazole Magnesium, Gabapentin, Glimepiride, Isoniazid, Losartan Potassium, Metformin HCl, Omeprazole, Pantoprazole Sodium, Pregabalin, Pyrazinamide, Rabeprazole Sodium, Rifampicin, Rivaroxaban, Sitagliptin Phosphate, Valsartan, Ivermectin, Sildenafil Citrate, Tadalafil, and product-specific requirements.

Share the API name, CAS number, grade requirement, pharmacopoeial reference such as IP, BP or USP, target quantity, destination country, required documents, packaging preference, storage condition, shipment timeline, and buyer type. Complete information helps CLAYRAS review the requirement more accurately.

Yes. Buyers may share the available product details, target application, expected pharmacopoeial reference, quantity, and destination country. CLAYRAS can coordinate a requirement-wise discussion, but final grade suitability must be reviewed based on buyer specifications, source documents, and regulatory expectations.

Yes. CLAYRAS supports product-level export discussions for selected Cortico-Steroids and corticosteroid APIs. These requirements are reviewed with product identity, CAS reference, grade, documentation context, source suitability, destination country, quantity, packaging, storage condition, and export feasibility.

Buyers can discuss selected products such as Beclomethasone Dipropionate, Betamethasone, Betamethasone Acetate, Betamethasone Dipropionate, Betamethasone Sodium Phosphate, Budesonide, Clobetasol Propionate, Deflazacort, Dexamethasone, Dexamethasone Sodium Phosphate, Difluprednate, Fludrocortisone Acetate, Fluocinolone Acetonide, Fluticasone Propionate, Halobetasol Propionate, Hydrocortisone, Methylprednisolone, Mometasone Furoate, Prednisolone, Triamcinolone, and related corticosteroid APIs.

GMP, GLP, DMF and other document context may be available depending on the product, source, manufacturer, quantity, commercial stage, and destination market. CLAYRAS does not treat document availability as guaranteed until the requirement is reviewed source-wise.

Cortico-Steroid APIs may require careful review because buyers often need product identity clarity, grade confirmation, impurity profile discussion, COA, MSDS, specification, DMF context, storage details, packaging details, and destination-market documentation alignment.

Yes. CLAYRAS supports requirement-wise discussions for selected Hormonal APIs and steroidal APIs. Final feasibility depends on product identity, source, grade, documentation, destination market, quantity, regulatory context, packaging, storage condition, and commercial terms.

Buyers can discuss selected products such as Hydroxyprogesterone Caproate, Progesterone, Norethisterone, Norethisterone Acetate, Nandrolone Decanoate, Testosterone Enanthate, Testosterone Propionate, Testosterone Decanoate, Testosterone Cypionate, Estradiol, Dydrogesterone, Mifepristone, Estradiol Valerate, Medroxyprogesterone Acetate, Levonorgestrel, Ethinyl Estradiol, Estradiol Cypionate, and other product-specific hormonal API requirements.

Yes. Hormonal APIs may require closer review of product identity, documentation, handling, source suitability, storage, packaging, destination-market expectations, and buyer qualification. CLAYRAS reviews such requirements product-wise and source-wise.

Hormonal APIs may have multiple esters, salts, hydrates, or closely related product forms. CAS number and exact product name help avoid confusion between variants such as Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate, Estradiol Valerate, Estradiol Benzoate, and Estradiol Cypionate.

Depending on the API, source, destination market, and commercial stage, documentation discussions may include COA, MSDS or SDS, TDS, product specification, DMF availability, CEP availability, Written Confirmation, GMP or GLP context, packaging details, storage condition, and other product or market-specific documents.

No. Document availability should not be treated as guaranteed before review. COA, MSDS, TDS, DMF, CEP, GMP, GLP, Written Confirmation, specification and other documents depend on product, source, manufacturer, batch, destination market, quantity, commercial stage, and applicable terms.

COA means Certificate of Analysis. It generally provides batch-specific analytical details for an API. Format, test parameters, availability, validity and sharing process depend on the product, source, batch, commercial stage and buyer requirement.

MSDS or SDS is a Safety Data Sheet. It provides safety, hazard, handling, storage, transport and emergency information for a material. It is commonly discussed during API procurement, packaging and shipment planning.

Yes. Documentation expectations can be discussed during the requirement review stage. Final DMF, CEP, Written Confirmation or other regulatory document availability depends on the API, source, destination market, buyer requirement, commercial terms and source approval.

Yes. CLAYRAS supports API export communication, requirement review, documentation coordination, packaging clarity, shipment planning discussion, destination-market context and buyer follow-up for international pharmaceutical API requirements.

Destination country affects import expectations, documentation discussion, shipment planning, packaging, logistics, regulatory context and commercial feasibility. Buyers should mention the destination country early in the inquiry.

Yes. Shipment mode, packaging, storage condition, incoterms, documentation and logistics expectations can be discussed during commercial coordination. Final arrangement depends on product, quantity, destination country, source and buyer requirements.

CLAYRAS works with pharmaceutical manufacturers, API importers, distributors, wholesalers, trading companies, regulatory teams, institutional buyers, research organizations and procurement departments seeking API supply support from India.

Yes. CLAYRAS supports bulk API requirement review, repeat procurement planning, export coordination and long-term pharmaceutical API supply communication for B2B buyers. Final commercial feasibility depends on product, quantity, source, documents and destination market.

Sample availability depends on API, source, regulatory nature of product, quantity, documentation expectations, commercial context and destination country. Buyers should share sample quantity, grade, documents required and intended use for review.

Buyers can request pricing or availability by sharing API name, CAS number, grade, quantity, destination country, documentation requirement, packaging preference, storage condition and procurement timeline. Incomplete requirements may delay review.

Yes. Buyers can discuss repeat procurement, annual planning, continuity-focused supply and long-term API export communication. The discussion depends on API, volume, frequency, market, documentation and commercial feasibility.

MOQ, price and lead time depend on API, quantity, source context, grade, packaging, documents, destination market, logistics and commercial terms. A clear requirement helps create a more accurate review.

Payment terms, commercial conditions, proforma invoice, shipment terms and timelines are generally discussed after product-level requirement review, source alignment, documentation discussion and quantity confirmation.

No claim should be treated as final until the requirement is reviewed. Availability, documents, MOQ, pricing, lead time, sample availability, packaging and export feasibility depend on product, source, quantity, destination market and commercial terms.